Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
Thierry André(Sorbonne Université), Elena Élez(Universitat Autònoma de Barcelona), Heinz‐Josef Lenz(University of Southern California), Lars Henrik Jensen(Vejle Sygehus), Yann Touchefeu(Centre Hospitalier Universitaire de Nantes), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Rocio García‐Carbonero(Hospital Universitario 12 De Octubre), David Tougeron(Centre Hospitalier Universitaire de Poitiers), Guillermo Ariel Mendez(Fundacion Favaloro Hospital Universitario), Michael Schenker(University of Medicine and Pharmacy of Craiova), Christelle de la Fouchardière(Centre Léon Bérard), María Luisa Limón(Hospital Universitario Virgen del Rocío), Takayuki Yoshino(National Cancer Center Hospital East), Jin Li(Shanghai East Hospital), José Luis Manzano Mozo(Institut Català d'Oncologia), Laëtitia Dahan(Aix-Marseille Université), Giampaolo Tortora(Agostino Gemelli University Polyclinic), Myriam Chalabi(Dutch Cancer Society), Eray Goekkurt(University Cancer Center Hamburg), Maria Ignez Braghiroli(Instituto do Câncer do Estado de São Paulo), Rohit Joshi, Timuçin Çil(Sağlık Bilimleri Üniversitesi), Francine Aubin(Centre Hospitalier de l’Université de Montréal), Elvis Cela(Bristol-Myers Squibb (United States)), Tian Chen(Bristol-Myers Squibb (United States)), Ming Lei(Bristol-Myers Squibb (United States)), Lixian Jin(Bristol-Myers Squibb (United States)), Steven I. Blum(Bristol-Myers Squibb (United States)), Sara Lonardi(Istituto Oncologico Veneto)
Cited by 167